RxDoctor Payments Data

Sriram Eleswarapu

Urology · Burbank, CANPI 1699015388

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.8%), speaking fees and grants — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Boston Scientific at 46.8% of the total. Reporting peaked in 2019 at $6,481 and has fallen 81.5% since, to $1,202 in 2025.

$17,196in general payments, 2019–2025

Across 108 payments — averaging $159.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$8K
  • Metuchen Pharmaceuticals$5K
  • Endo Pharmaceuticals Inc.$1K
  • Coloplast$795
  • Antares Pharma, Inc.$702
  • Endo USA, Inc.$458
  • plus $794 from 9 others

What the payments were for

  • Consulting fees$2501%
  • Speaking & faculty fees$4,60027%
  • Grants$4,00823%
  • Travel & lodging$70%
  • Food & beverage$8,05147%
  • Education$2802%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,196 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024
$190,806
Medicare patients
155
Services billed
17,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyostedTestosterone Enanthate18$10,956
Testosterone55$5,303
Testosterone Cypionate52$3,103
Tamsulosin Hcl141$1,805
Trospium Chloride24$1,276
Alfuzosin Hcl ErAlfuzosin Hcl12$992
Finasteride50$892
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Antares Pharma, Inc.Xyosted$702$10,95618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Burbank

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →